SRRK
Scholar RockBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readouts and a constructive partnership or commercial update validate the mechanism and could re-rate shares toward the analyst high (63.0). Limited near-term dilution and clear regulatory progress would reinforce upside within 12 months.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -6.6.
What can break
Clinical trial failure or missed endpoints
Momentum
65
Value
41
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $50.34 · Bull $63.00 · Bear $42.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-04 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $55.69
Why
Momentum65 · Δ7d -6.6
Value41 · Δ7d +0.1
Sentiment64 · Δ7d +5.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
65
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.6
Δ21d
+20.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
64
33% active weight
Current posture
7d trendImproving
Δ7d
+5.2
Δ21d
+10.4
Why this grade
Composite grade B. Momentum 65.3 / Value 41.1 / Sentiment 63.6
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$5.35B
Beta
0.69
Shares Out
102.01M
P/E (TTM) · Derived
-15.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-21.40
Rev YoY
-
EPS YoY
-35.3%
Gross Margin
-
Op Margin
-
Net Debt
-$387.13M
Current Ratio
6.30
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology